A Case Registration Study for Naoshuantong Capsule in the Treatment of Ischemic Stroke Based on the Theory of Cerebral Collaterals Injury by Toxin

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025053

Enrollment

Unknown

Registered

2019-08-09

Start date

2019-09-02

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Case Series:N/A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who meet the criteria for the diagnosis of acute ischemic stroke formulated in the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018 issued by the Neurological Society of the Chinese Medical Association; 2. The course of disease is less than one month. 3. Naoshuantong capsule prescribed by doctors.

Exclusion criteria

Exclusion criteria: Combined with other diseases that affect the evaluation of neurological function and life ability.

Design outcomes

Primary

Measure	Time frame
Degree of disability;Degree of neurological impairment;Activity of daily living;Cognitive level;Diagnostic Scale for Syndrome Elements of Ischemic Stroke;Endpoint of efficacy (mortality, recurrence rate);	—

Countries

CHINA

Contacts

Public ContactYing Gao

Dongzhimen Hospital, Beijing University of Chinese Medicine

arthasdxl@163.com+86 13366275973

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026